Zimbabwe has rejected a major US health deal worth $367m (272 million pounds) over five years due to the United States' demand for sensitive data.
This move was revealed after a official document from December was leaked, revealing that President Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesman later explained that the United States was seeking genetic material for research and commercial gain but was not willing to guarantee the benefits from any future treatments.
"We will now turn to the difficult and regrettable process of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has called for further talks to secure a agreement suitable to both sides so the nation's vital HIV treatment initiative can be sustained.
Broader Background
Zimbabwe's decision comes after a similar case in Kenya, where a high court blocked a related deal with the US after legal challenges were raised about the security of Kenyans' health data.
Since resuming office last year, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump argued its spending was "wasteful" and his government was seeking government-to-government agreements to boost openness and responsibility.
According to reports, Sixteen nations in Africa have so far agreed to similar agreements, representing over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation would have delivered immense benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy through US-supported programmes," Tremont commented.
However, official spokesman Nick Mangwana said the proposed deal was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, with no equivalent promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"Put simply, our nation would supply the basic resources for medical research without any certainty that the resulting innovations would be available to our population should a future health crisis arise."
Sovereignty and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending systems previously established via the international organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to deal with future global health emergencies.
"This framework is intended to guarantee that when a nation provides its samples, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to create them."
The government's concerns over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We are open to ongoing dialogue with our American counterparts on how future co-operation might be structured in a way that respects the independence and dignity of each country."
Health Experts Response
A leading public health body expressed it acknowledged the government's concerns, but suggested that talks should continue since much of the nation's Aids initiatives relied on external financing.
"In cases where specific concerns exist, including those relating to data governance or implementation frameworks, these can frequently be resolved through technical clarification and mutually agreed protections," it added.
The situation highlights the ongoing debate between accepting much-needed foreign assistance and protecting national sovereignty in an ever more data-driven world.